PMID: 7426828Sep 1, 1980Paper

Electrophysiological effects of imipramine on bovine ventricular muscle and Purkinje fibres

British Journal of Pharmacology
S Rodriguez, J Tamargo


1 The effect of imipramine in concentrations between 0.01 microM and 50 microM has been studied on bovine Purkinje fibres and ventricular muscle transmembrane potentials. 2 In electrically stimulated fibres, imipramine had no effect on the resting membrane potential, but decreased the action potential amplitude, overshoot and maximum rate of depolarization (Vmax). 3 In Purkinje fibres, imipramine also decreased the conduction velocity and shifted the membrane responsiveness and recovery time curves downward and to the right. 4 In both Purkinje fibres and ventricular muscle, imipramine decreased the amplitude of phase 2 and prolonged phase 3. In Purkinje fibres, imipramine did not alter the action potential duration (APD) but prolonged the effective refractory period (ERP). In ventricular muscle, at concentrations higher than 1 microM imipramine shortened both the APD and the ERP and made the ERP long as compared to APD. 5 Imipramine decreased the slope of phase 4 diastolic depolarization in spontaneously beating Purkinje fibres. 6 These properties of imipramine are quite similar to those of quinidine or procainamide (class 1 antiarrhythmics). The mechanisms responsible for the cardiac effect of imipramine are discussed.


Jan 27, 1977·The New England Journal of Medicine·J T BiggerA H Glassman
Apr 15, 1979·European Journal of Pharmacology·J TamargoP Garcia de Jaloń
Mar 24, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·E CarmelietR Reneman
Feb 1, 1975·Australian and New Zealand Journal of Medicine·J VohraG Sloman
Jan 1, 1973·Circulation·P F CranefieldB F Hoffman
May 1, 1973·Archives of General Psychiatry·A H Glassman, J M Perel
Mar 1, 1971·The Journal of General Physiology·G Giebisch, S WEIDMANN
Sep 1, 1958·British Journal of Pharmacology and Chemotherapy·E M VAUGHAN WILLIAMS
Oct 1, 1960·Archives of Surgery·E HOFFMAN
Jan 1, 1961·Acta Psychiatrica Scandinavica·E S Kristiansen
Jan 1, 1964·Medicina Experimentalis. International Journal of Experimental Medicine·M FEKETE, J BORSY
Mar 1, 1962·The Journal of Physiology·L Szekeres, E M Williams


Aug 4, 2010·Cardiovascular Toxicology·Yoshitaka MitsumoriAtsushi Sugiyama
Nov 11, 1983·European Journal of Pharmacology·T TejerinaJ Tamargo
Jan 22, 1985·European Journal of Pharmacology·G Isenberg, J Tamargo
Jun 18, 1991·European Journal of Pharmacology·F Pérez-VizcainoJ Tamargo
Sep 19, 1996·European Journal of Pharmacology·A YoshidaC Shigemasa
Jan 1, 1989·General Pharmacology·M ManoachM Erez
Oct 23, 1997·Critical Care Clinics·P F Kolecki, S C Curry
Jan 1, 1989·Psychological Medicine. Monograph Supplement·S J WarringtonM Lader
Jun 1, 1992·British Journal of Pharmacology·E DelpónJ Sánchez-Chapula
Nov 2, 2011·The Veterinary Journal·R SacchettoF Mascarello
Jan 1, 1987·Journal of Clinical Pharmacology·C M Lathers, L J Lipka
Jan 1, 1989·Fundamental & Clinical Pharmacology·R H RouetB A Dupuis
Mar 18, 2011·Journal of Cellular Physiology·Michele CarboneHaining Yang
Mar 1, 1987·British Journal of Pharmacology·C DelgadoC Valenzuela
May 1, 1982·British Journal of Pharmacology·S BarrigonT Tejerina
Nov 1, 1985·British Journal of Pharmacology·J DiezC Valenzuela
May 1, 1983·British Journal of Pharmacology·J Manzanares, J Tamargo
Mar 1, 1986·Medical Toxicology·P R Pentel, N L Benowitz
Feb 1, 1986·British Journal of Pharmacology·C DelgadoC Valenzuela

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.